Cytokinetics Inc gross margin has been in long-term decline. The average rate of decline per year is -54.6%.
The historical rank and industry rank for Cytokinetics's Gross Margin % or its related term are showing as below:
CYTK'
s Gross Margin % Range Over the Past 10 Years
Min: -4284.1 Med: -140.84 Max: 43.71
Current: -4284.1
During the past 13 years, the highestGross Margin % of Cytokinetics was 43.71%. The lowest was -4284.10%. And the median was -140.84%.
CYTK's Gross Margin % is ranked worse than 99.73% of 736
companies
in the Biotechnology industry
Industry Median: 59.655
vs CYTK: -4284.10
Cytokinetics had a gross margin of -4,982.30% for the quarter that ended in Dec. 2023 => No sustainable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Cytokinetics was -54.60% per year.
Cytokinetics Gross Margin % Historical Data
The historical data trend for Cytokinetics's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Cytokinetics's Gross Margin %
For the Biotechnology subindustry, Cytokinetics's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cytokinetics's Gross Margin % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cytokinetics's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Cytokinetics's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Cytokinetics had a gross margin of -4,982.30% for the quarter that ended in Dec. 2023 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Cytokinetics Gross Margin % Related Terms
Thank you for viewing the detailed overview of Cytokinetics's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CYTK has been successfully added to your 